Research programme: malaria vaccine - Etna

Drug Profile

Research programme: malaria vaccine - Etna

Latest Information Update: 20 Mar 2014

Price : $50

At a glance

  • Originator Etna Biotech
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malaria

Most Recent Events

  • 20 Mar 2014 Preclinical development is ongoing in Italy
  • 27 Dec 2006 Preclinical trials in Malaria in Italy (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top